Prostate cancer is one of the most common cancers in men. When the disease progresses, doctors often prescribe hormone-based therapies that target the androgens fueling tumor growth. One common approach is maximal androgen blockade (MAB)—combining traditional androgen deprivation therapy (ADT) with drugs that block androgen receptor signaling. These add-on medications include abiraterone acetate, enzalutamide, apalutamide, and darolutamide. Some patients also receive older anti-androgens like flutamide, bicalutamide, or nilutamide. A systematic review and meta-analysis published in early 2026 in Prostate Cancer and Prostatic Diseases asked a straightforward question: does adding these androgen receptor pathway inhibitors to standard hormone therapy increase fracture risk? The research team analyzed 17 clinical trials with more than 16,000 patients…